Psychedelic Bulletin: Psychedelics X Big Pharma; $23m Round for At-Home Ketamine Therapy; Psychedelics Research Review Post published:April 25, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse Stock-Split; Are Magic Mushrooms Giving Investors a Bad Trip? Post published:April 15, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On Post published:April 8, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1, 2022) Post published:April 1, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing Footage Emerges from MAPS Trial Post published:March 25, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MINDCURE – A Canary in the Psychedelic Coal Mine? Post published:March 18, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Tensions Rise Among Oregon’s Psilocybin Advisory Board; Colleges Team up to Develop Psychedelic Curriculum Post published:March 11, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead for Psychedelic Medicine Post published:March 7, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Following the Money – How Much do Psychedelics Companies Spend on R&D? Post published:February 28, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Tracking LSD Patents; Psilocybin Effective for a Year in Depression; Cybin Partners with Chopra Foundation Post published:February 18, 2022 Post category:Psychedelic Bulletin